Labcorp (LH) EVP and Chief Legal Officer sells 762 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported an open-market sale of Common Stock. On June 8, 2026, she sold 762 shares at $263.89 per share in a transaction made under a pre-arranged Rule 10b5-1 trading plan. After this sale, she directly owns about 3,813.4574 shares of Labcorp common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 762 shares ($201,084)
Net Sell
1 txn
Insider
Kyle Kathryn W
Role
EVP, Chief Legal Officer
Sold
762 shs ($201K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 762 | $263.89 | $201K |
Holdings After Transaction:
Common Stock — 3,813.457 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares sold: 762 shares
Sale price: $263.89 per share
Shares held after transaction: 3,813.4574 shares
3 metrics
Shares sold
762 shares
Open-market sale of Labcorp Common Stock on June 8, 2026
Sale price
$263.89 per share
Price for the 762 Labcorp shares sold
Shares held after transaction
3,813.4574 shares
Direct Labcorp Common Stock holdings after the sale
Key Terms
Rule 10b5-1, open-market sale, Common Stock, Form 4
4 terms
Rule 10b5-1 regulatory
"Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Labcorp (LH) disclose for Kathryn W. Kyle?
Labcorp disclosed that EVP and Chief Legal Officer Kathryn W. Kyle sold 762 shares of Common Stock. The open-market sale occurred on June 8, 2026 at $263.89 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.
What are Kathryn W. Kyle’s Labcorp (LH) holdings after the reported sale?
Following the reported transaction, Kathryn W. Kyle directly holds about 3,813.4574 shares of Labcorp Common Stock. This figure reflects her position after selling 762 shares in the June 8, 2026 open-market sale under a Rule 10b5-1 plan.
Was the Labcorp (LH) insider sale by Kathryn W. Kyle under a Rule 10b5-1 plan?
Yes, the filing states the sale was made pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged under SEC rules and indicate the timing of transactions is scheduled in advance rather than based on current market information.
What role does Kathryn W. Kyle hold at Labcorp (LH) in this Form 4 filing?
Kathryn W. Kyle is identified as an officer of Labcorp, serving as Executive Vice President and Chief Legal Officer. The Form 4 reports her direct ownership of common shares and the June 8, 2026 open-market sale of 762 Labcorp shares.